Last reviewed · How we verify

Recurrent Persistent Urethritis — Treatment Landscape & Competitive Intelligence

Recurrent Persistent Urethritis (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Recurrent Persistent Urethritis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Benzamycin Erythromycin Lactobionate Pfizer Macrolide Potassium voltage-gated channel subfamily H member 2 1964-01-01
E-Mycin erythromycin Generic (originally Abbott/Lilly) Macrolide [EPC] Aldehyde oxidase, Bile salt export pump, Cytochrome P450 1B1 1952-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Generic (originally Abbott/Lilly) · 1 drug in Recurrent Persistent Urethritis
  2. Pfizer · 1 drug in Recurrent Persistent Urethritis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Recurrent Persistent Urethritis:

Cite this brief

Drug Landscape (2026). Recurrent Persistent Urethritis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/recurrent-persistent-urethritis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing